These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 37459794

  • 21. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
    Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett AC, Viglietta V, Greenberg SJ.
    J Neurol; 2013 Apr; 260(4):1136-46. PubMed ID: 23263473
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis.
    Rau D, Müller B, Übler S.
    Adv Ther; 2023 Dec; 40(12):5547-5556. PubMed ID: 37776477
    [Abstract] [Full Text] [Related]

  • 24. CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis.
    Marastoni D, Foschi M, Eccher C, Crescenzo F, Mazziotti V, Tamanti A, Bajrami A, Camera V, Ziccardi S, Guandalini M, Bosello F, Anni D, Virla F, Turano E, Romoli M, Mariotti R, Pizzini FB, Bonetti B, Calabrese M.
    Front Immunol; 2024 Dec; 15():1343892. PubMed ID: 38404586
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop).
    Schiavetti I, Signori A, Albanese A, Frau J, Cocco E, Lorefice L, di Lemme S, Fantozzi R, Centonze D, Landi D, Marfia G, Signoriello E, Lus G, Zecca C, Gobbi C, Iodice R, Malimpensa L, Cordioli C, Ferraro D, Ruscica F, Pasquali L, Repice A, Immovilli P, Ferrò MT, Bonavita S, Di Filippo M, Abbadessa G, Govone F, Sormani MP, CladStop study group.
    Eur J Neurol; 2024 Jun; 31(6):e16250. PubMed ID: 38549186
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
    Rauma I, Viitala M, Kuusisto H, Atula S, Sipilä JOT, Ryytty M, Soilu-Hänninen M, Järvinen E.
    Mult Scler Relat Disord; 2022 May; 61():103755. PubMed ID: 35483129
    [Abstract] [Full Text] [Related]

  • 30. Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing.
    Manni A, Oggiano F, Palazzo C, Panetta V, Gargano CD, Mangialardi V, Guerra T, Iaffaldano A, Caputo F, Iaffaldano P, Ruggieri M, Trojano M, Paolicelli D.
    J Neurol Sci; 2024 Jul 15; 462():123070. PubMed ID: 38850773
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B, Guerreiro R, Costa J, Miguel LS.
    J Med Econ; 2020 May 15; 23(5):484-491. PubMed ID: 31951777
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. High persistence and low adverse events burden in cladribine treated MS patients from Argentina.
    Negrotto L, Iut VC, Etchepare A, D'Eramo M, Grinspan A, Assefi A.
    Mult Scler Relat Disord; 2022 Dec 15; 68():104403. PubMed ID: 36544327
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.